Bessemer Group Inc. Sells 6,502 Shares of Repligen Co. (NASDAQ:RGEN)

Bessemer Group Inc. trimmed its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 2.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 248,689 shares of the biotechnology company's stock after selling 6,502 shares during the period. Bessemer Group Inc. owned approximately 0.44% of Repligen worth $35,796,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Signaturefd LLC lifted its position in shares of Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 124 shares in the last quarter. Sava Infond d.o.o. bought a new stake in Repligen during the 4th quarter worth about $29,000. Resources Management Corp CT ADV acquired a new position in shares of Repligen during the 3rd quarter worth about $37,000. Quarry LP boosted its stake in shares of Repligen by 796.7% during the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company's stock worth $40,000 after buying an additional 239 shares during the last quarter. Finally, UMB Bank n.a. grew its holdings in shares of Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 110 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on RGEN shares. JPMorgan Chase & Co. boosted their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. TD Cowen started coverage on Repligen in a research report on Monday, February 10th. They issued a "buy" rating and a $200.00 target price on the stock. StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a report on Friday, April 4th. Canaccord Genuity Group began coverage on Repligen in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective on the stock. Finally, Canaccord Genuity Group increased their price objective on Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a research report on Friday, February 21st. Seven investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $178.64.

Repligen Trading Down 1.2 %

Shares of RGEN stock traded down $1.55 on Tuesday, hitting $125.71. The company had a trading volume of 364,178 shares, compared to its average volume of 700,434. The firm has a market cap of $7.06 billion, a P/E ratio of -246.49, a P/E/G ratio of 4.54 and a beta of 1.27. The stock's 50-day moving average is $142.43 and its two-hundred day moving average is $146.19. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a twelve month low of $102.97 and a twelve month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. On average, equities research analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In related news, Director Margaret Pax bought 250 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the transaction, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by company insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.